EQT Life Sciences leads EUR 93 million oversubscribed Series A round in PanTera, which aims to accelerate global actinium - 225 production

EQT Sweden

On track for commercial-scale production of actinium-225, which is crucial to a new class of targeted treatments for cancerLargest Series A in life sciences sector in Belgium to date; led by EQT Life SciencesTotal of EUR 134 million raised including funding secured through EUR 7.2 million equity from IBA and SFPIM, and EUR 33.8 million debt financingView original content:https://www.prnewswire.co.uk/news-releases/eqt-life-sciences-leads-eur-93-million-oversubscribed-series-a-round-in-pantera-which-aims-to-accelerate-global-actinium---225-production-302244845.html